pioneer 8 semaglutide Dose-response, efficacy, and safety of oral monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial Insulin-sparing Effects of Oral Semaglutide:

By synergistically integrating GLP-1, amylin, and calcitonin receptor signaling, it effectively overcomes the efficacy ceilings of current monotherapies, offering profound weight reduction and glycemic control comparable to surgical interventions. For now, we must wait and see

Endocrinology 133:233240 Roberge JN, Gronau KA, Brubaker PL (1996) Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut

Recently it has been observed with some kidney-related benefits in patients with heart disease

3-7 Hypoglycaemia can lead to loss of consciousness and even death

(PubMed) Nuclear Regulatory Commission